Home
>
US Stocks
>
Dynavax Technologies Corporation

Dynavax Technologies Corporation (DVAX)

$11.39

-0.42

(-3.56%)▲

Market is closed - opens 7 PM, 12 Jun 2023

Performance

  • $11.28
    $11.82
    $11.39
    downward going graph

    0.97%

    Downside

    Day's Volatility :4.57%

    Upside

    3.64%

    downward going graph
  • $9.42
    $17.48
    $11.39
    downward going graph

    17.3%

    Downside

    52 Weeks Volatility :46.11%

    Upside

    34.84%

    downward going graph

Returns

PeriodDynavax Technologies Corporation
3 Months
17.32%
6 Months
1.74%
1 Year
-0.39%
3 Years
40.75%

Highlights

Market Capitalization
1.5B
Book Value
$4.39
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
1.57
PE Ratio
7.25
PEG Ratio
0.0
Wall Street Target Price
22.8
Profit Margin
35.99%
Operating Margin TTM
40.19%
Return On Assets TTM
16.64%
Return On Equity TTM
55.44%
Revenue TTM
655.6M
Revenue Per Share TTM
5.15
Quarterly Revenue Growth YOY
-58.8%
Gross Profit TTM
448.2M
EBITDA
267.3M
Diluted Eps TTM
1.57
Quarterly Earnings Growth YOY
-0.31
EPS Estimate Current Year
-0.53
EPS Estimate Next Year
-0.25
EPS Estimate Current Quarter
-0.13
EPS Estimate Next Quarter
-0.12

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Dynavax Technologies Corporation(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 100.18%

Current $11.39
Target $22.80

Company Financials

FY17Y/Y Change
Revenue
327.0K
↓ 97.04%
Net Income
-95.2M
↓ 15.38%
Net Profit Margin
-29.1K%
↓ 28080.84%
FY18Y/Y Change
Revenue
8.2M
↑ 2407.03%
Net Income
-158.9M
↑ 66.99%
Net Profit Margin
-1.9K%
↑ 27160.81%
FY19Y/Y Change
Revenue
35.2M
↑ 329.6%
Net Income
-152.6M
↓ 3.96%
Net Profit Margin
-433.29%
↑ 1504.98%
FY20Y/Y Change
Revenue
46.6M
↑ 32.18%
Net Income
-75.2M
↓ 50.69%
Net Profit Margin
-161.63%
↑ 271.66%
FY21Y/Y Change
Revenue
439.4M
↑ 844.0%
Net Income
76.7M
↓ 201.96%
Net Profit Margin
17.46%
↑ 179.09%
FY22Y/Y Change
Revenue
722.7M
↑ 64.45%
Net Income
293.2M
↑ 282.15%
Net Profit Margin
40.56%
↑ 23.1%
Q4 FY21Q/Q Change
Revenue
195.1M
↑ 80.17%
Net Income
99.8M
↓ 450.96%
Net Profit Margin
51.15%
↑ 77.41%
Q1 FY22Q/Q Change
Revenue
114.0M
↓ 41.56%
Net Income
32.9M
↓ 67.07%
Net Profit Margin
28.83%
↓ 22.32%
Q2 FY22Q/Q Change
Revenue
256.5M
↑ 124.98%
Net Income
128.8M
↑ 291.84%
Net Profit Margin
50.2%
↑ 21.37%
Q3 FY22Q/Q Change
Revenue
167.7M
↓ 34.6%
Net Income
63.8M
↓ 50.44%
Net Profit Margin
38.04%
↓ 12.16%
Q4 FY22Q/Q Change
Revenue
184.5M
↑ 9.99%
Net Income
67.7M
↑ 6.15%
Net Profit Margin
36.71%
↓ 1.33%
Q1 FY23Q/Q Change
Revenue
46.9M
↓ 74.57%
Net Income
-24.3M
↓ 135.92%
Net Profit Margin
-51.85%
↓ 88.56%
FY17Y/Y Change
Total Assets
218.8M
↑ 99.48%
Total Liabilities
19.2M
↓ 6.07%
FY18Y/Y Change
Total Assets
210.9M
↓ 3.61%
Total Liabilities
147.8M
↑ 668.45%
FY19Y/Y Change
Total Assets
279.1M
↑ 32.33%
Total Liabilities
270.8M
↑ 83.18%
FY20Y/Y Change
Total Assets
353.3M
↑ 26.59%
Total Liabilities
294.6M
↑ 8.79%
FY21Y/Y Change
Total Assets
1.0B
↑ 194.18%
Total Liabilities
816.9M
↑ 177.3%
FY22Y/Y Change
Total Assets
985.9M
↓ 5.14%
Total Liabilities
404.8M
↓ 50.44%
Q4 FY21Q/Q Change
Total Assets
1.0B
↑ 13.0%
Total Liabilities
816.9M
↓ 4.14%
Q1 FY22Q/Q Change
Total Assets
1.0B
↓ 2.91%
Total Liabilities
721.5M
↓ 11.68%
Q2 FY22Q/Q Change
Total Assets
1.0B
↑ 1.39%
Total Liabilities
600.2M
↓ 16.81%
Q3 FY22Q/Q Change
Total Assets
999.3M
↓ 2.31%
Total Liabilities
498.8M
↓ 16.9%
Q4 FY22Q/Q Change
Total Assets
985.9M
↓ 1.35%
Total Liabilities
404.8M
↓ 18.83%
Q1 FY23Q/Q Change
Total Assets
969.9M
↓ 1.62%
Total Liabilities
406.2M
↑ 0.33%
FY17Y/Y Change
Operating Cash Flow
-77.5M
↓ 27.59%
Investing Cash Flow
-108.7M
↓ 226.03%
Financing Cash Flow
187.8M
↑ 35275.14%
FY18Y/Y Change
Operating Cash Flow
-131.3M
↑ 69.38%
Investing Cash Flow
55.5M
↓ 151.03%
Financing Cash Flow
99.1M
↓ 47.26%
FY19Y/Y Change
Operating Cash Flow
-121.3M
↓ 7.65%
Investing Cash Flow
-42.8M
↓ 177.13%
Financing Cash Flow
154.4M
↑ 55.8%
FY20Y/Y Change
Operating Cash Flow
-92.3M
↓ 23.92%
Investing Cash Flow
-26.5M
↓ 37.98%
Financing Cash Flow
109.5M
↓ 29.06%
FY21Y/Y Change
Operating Cash Flow
335.5M
↓ 463.71%
Investing Cash Flow
14.2M
↓ 153.61%
Financing Cash Flow
55.8M
↓ 49.06%
Q4 FY21Q/Q Change
Operating Cash Flow
120.5M
↑ 81.99%
Investing Cash Flow
54.9M
↑ 20.29%
Financing Cash Flow
14.8M
↑ 178.39%
Q1 FY22Q/Q Change
Operating Cash Flow
-50.4M
↓ 141.86%
Investing Cash Flow
-216.5M
↓ 494.05%
Financing Cash Flow
10.3M
↓ 30.57%
Q2 FY22Q/Q Change
Operating Cash Flow
16.7M
↓ 133.01%
Investing Cash Flow
52.5M
↓ 124.25%
Financing Cash Flow
1.0M
↓ 90.01%
Q3 FY22Q/Q Change
Operating Cash Flow
61.6M
↑ 269.71%
Investing Cash Flow
-119.0M
↓ 326.75%
Financing Cash Flow
8.1M
↑ 683.75%
Q1 FY23Q/Q Change
Operating Cash Flow
27.6M
↓ 20.96%
Investing Cash Flow
-52.3M
-
Financing Cash Flow
-3.1M
↓ 2119.61%

Technicals Summary

Sell

Neutral

Buy

Dynavax Technologies Corporation is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Dynavax Technologies Corporation
Dynavax Technologies Corporation
4.34%
1.74%
-0.39%
40.75%
40.75%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-3.43%
-21.81%
-0.94%
-21.05%
-5.78%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
-7.07%
4.76%
9.99%
9.99%
9.99%
Zoetis Inc.
Zoetis Inc.
-11.91%
6.69%
0.99%
16.57%
87.33%
Viatris Inc.
Viatris Inc.
-2.11%
-15.73%
-16.18%
-42.55%
-42.55%
Catalent, Inc.
Catalent, Inc.
15.54%
-14.7%
-63.62%
-48.0%
-2.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Dynavax Technologies Corporation
Dynavax Technologies Corporation
7.25
7.25
0.0
-0.53
0.55
0.17
0.0
4.39
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
151.66
151.66
1.87
1.93
0.04
0.08
0.0
17.28
Haleon Plc Spon Ads
Haleon Plc Spon Ads
27.5
27.5
NA
0.0
0.05
0.04
0.01
3.54
Zoetis Inc.
Zoetis Inc.
35.69
35.69
3.53
5.4
45.26
0.13
0.01
9.72
Viatris Inc.
Viatris Inc.
6.01
6.01
NA
2.95
0.09
0.03
0.05
17.45
Catalent, Inc.
Catalent, Inc.
16.84
16.84
1.18
1.37
0.09
0.04
0.0
27.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Dynavax Technologies Corporation
Dynavax Technologies Corporation
Buy
$1.5B
40.75%
7.25
35.99%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$9.2B
-5.78%
151.66
4.0%
Haleon Plc Spon Ads
Haleon Plc Spon Ads
Buy
$38.2B
9.99%
27.5
9.86%
Zoetis Inc.
Zoetis Inc.
Buy
$75.6B
87.33%
35.69
25.59%
Viatris Inc.
Viatris Inc.
Hold
$11.3B
-42.55%
6.01
12.05%
Catalent, Inc.
Catalent, Inc.
Buy
$7.1B
-2.17%
16.84
8.62%

Institutional Holdings

  • BlackRock Inc

    14.85%

  • Federated Hermes Inc

    9.85%

  • State Street Corporation

    6.96%

  • Vanguard Group Inc

    6.58%

  • Deep Track Capital, LP

    4.94%

  • Chicago Capital, LLC

    4.55%

Company Information

dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.

Organization
Dynavax Technologies Corporation
Employees
351
CEO
Mr. Ryan Spencer
Industry
Health Technology

Discover More

FAQs